Design Therapeutics Inc., a clinical-stage biotechnology company, has reported its financial results for the second quarter of 2025. The company recorded a net loss of $19.1 million for the quarter ended June 30, 2025. Research and development expenses amounted to $15.7 million, while general and administrative expenses totaled $5.8 million for the same period. As of June 30, 2025, Design Therapeutics held $216.3 million in cash, cash equivalents, and investment securities. The company highlighted significant progress in its GeneTAC® programs, notably reporting favorable early human pharmacokinetics data for DT-216P2. This candidate demonstrated consistent translation from non-human primates to humans and showed an improved product profile for its Friedreich Ataxia program compared to the prior formulation. Design Therapeutics also initiated a Phase 2 biomarker study for DT-168 in patients with Fuchs Endothelial Corneal Dystrophy. Additionally, despite receiving a clinical hold notice from the U.S. Food and Drug Administration regarding the starting dose in the U.S. for DT-216P2, the company continues to dose patients in its RESTORE-FA Phase 1/2 multiple-ascending dose trial outside the U.S. Looking ahead, Design Therapeutics plans to select a development candidate for its myotonic dystrophy type-1 program later in 2025 and continues to advance preclinical activities for Huntington's disease.